News

Shimadzu Corporation and Shimadzu Scientific Instruments (SSI) announce they have joined the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public–private partnership dedicated to advancing biopharmaceutical manufacturing technologies in the United States.

Through participation in NIIMBL, SSI, the North American subsidiary of Shimadzu Corporation’s Analytical and Measuring Instruments Division, will engage in collaborative projects that focus on improving process understanding, manufacturing robustness, and data-driven decision-making across the biopharmaceutical lifecycle.

“Shimadzu Scientific Instruments’ participation in NIIMBL reflects our commitment to accelerating the translation of biopharmaceutical innovation into scalable, reliable manufacturing practices,” said Yusuke Nagai, Product Strategy Manager at SSI. “By collaborating with NIIMBL members across industry, academia, and government, we aim to advance analytical technologies that support robust process development, quality by design, and next-generation biologics manufacturing.”

SSI’s involvement aligns with its broader mission to support customers in reducing development risk, improving reproducibility, and implementing manufacturing-ready analytics that meet evolving regulatory and quality expectations.

“NIIMBL provides a unique ecosystem where analytical science, biomanufacturing, and workforce development intersect,” Nagai added. “SSI looks forward to contributing measurement and data strategies and collaborating with the next generation of biopharmaceutical manufacturing leaders.”

NIIMBL leadership welcomed SSI’s participation as a valuable addition to the institute’s collaborative community.

As a NIIMBL member, Shimadzu will collaborate with partners across the biopharmaceutical value chain to support innovation that accelerates manufacturing readiness while maintaining quality, regulatory confidence, and patient impact.